Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults.

ABSTRACT:

Background

Despite significant advances in therapeutic management of atypical hemolytic uremic syndrome (aHUS), guidelines are not timely updated and achieving a consensus on management recommendations remains a topic of ongoing discussion.

Methods

A Scientific Committee with five experts was set up. A literature review was conducted and publications addressing the classification of aHUS, patient profiles and therapeutic approach were selected. Recommendations were proposed at an initial meeting, evaluated through an online questionnaire and validated during a second meeting.

Results

Patients with confirmed or clear suspicion of aHUS should be treated with C5 inhibitors within 24 h of the diagnosis or suspicion of aHUS. Treatment monitoring and the decision to interru

SUBMITTER: Avila A 

PROVIDER: S-EPMC10722909 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature